Equities Analysts Offer Predictions for ADAP Q1 Earnings

Adaptimmune Therapeutics plc (NASDAQ:ADAP) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Adaptimmune Therapeutics in a research report issued on Thursday, November 14th. HC Wainwright analyst A. He anticipates that the biotechnology company will post earnings per share of ($0.18) for the quarter. HC Wainwright has a “Buy” rating and a $3.50 price target on the stock. The consensus estimate for Adaptimmune Therapeutics’ current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Adaptimmune Therapeutics’ Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.12) EPS.

Several other equities research analysts have also issued reports on the stock. Guggenheim lowered their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Friday. StockNews.com lowered Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $3.16.

Adaptimmune Therapeutics Price Performance

Shares of ADAP opened at $0.59 on Friday. The company has a quick ratio of 3.09, a current ratio of 3.09 and a debt-to-equity ratio of 0.26. The business has a fifty day moving average of $0.88 and a 200 day moving average of $1.03. The company has a market cap of $150.02 million, a PE ratio of -2.67 and a beta of 2.26. Adaptimmune Therapeutics has a 52-week low of $0.42 and a 52-week high of $2.05.

Institutional Trading of Adaptimmune Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Long Focus Capital Management LLC increased its holdings in Adaptimmune Therapeutics by 15.6% during the 2nd quarter. Long Focus Capital Management LLC now owns 12,346,417 shares of the biotechnology company’s stock worth $12,037,000 after purchasing an additional 1,662,184 shares during the period. Baillie Gifford & Co. grew its position in shares of Adaptimmune Therapeutics by 10.7% during the 3rd quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock worth $15,944,000 after buying an additional 1,626,657 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Adaptimmune Therapeutics by 28.3% during the second quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock valued at $1,742,000 after buying an additional 394,566 shares during the period. GSA Capital Partners LLP bought a new stake in shares of Adaptimmune Therapeutics in the third quarter valued at about $95,000. Finally, Jane Street Group LLC raised its holdings in shares of Adaptimmune Therapeutics by 130.4% in the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 98,581 shares in the last quarter. Institutional investors own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.